Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Orbitz Worldwide, Inc. (OWW), Vical Incorporated (VICL), MannKind Corporation (MNKD): Last Week’s Biggest Losers

There’s never a shortage of losers in the stock market. Let’s take a closer look at five of this past week’s biggest sinkers.

Company Aug. 16 Weekly Loss
Vical Incorporated (NASDAQ:VICL)
$1.40 61%
MannKind Corporation (NASDAQ:MNKD) $5.77 23%
Orbitz Worldwide, Inc. (NYSE:OWW) $9.68 18%
Portugal Telecom, SGPS (ADR) (NYSE:PT
$3.76 10%
Kandi Technologies Group Inc (NASDAQ:KNDI)
$4.44 10%

Source: Barron’s.

Let’s start with Vical Incorporated (NASDAQ:VICL). The biotech shed more than half of its value after abandoning its once promising Allovectin program. Data from the potential cancer tumor-shrinking treatment’s late-stage trial failed to meet the study’s efficacy goals.

Vical Incorporated (NASDAQ:VICL)

Vical Incorporated (NASDAQ:VICL) will turn its attention to infectious disease vaccine programs, but the rigorous and lengthy approval process in getting a new treatment to market isn’t going to fly with investors who were hoping for Vical Incorporated (NASDAQ:VICL) to have a product on the market sooner rather than later.

MannKind Corporation (NASDAQ:MNKD) is another company that took a hit on late-stage trial news, but this announcement was initially taken as a positive. Shares of MannKind Corporation (NASDAQ:MNKD) popped higher announcing positive efficacy results for its inhalable insulin treatment for both primary types of diabetes.

It could have been a case of “sell on the news” kicking in. Impatient investors also may have gotten cold feet, since regulatory approval won’t be completed until next year at the earliest.

There were also a couple of small negatives. The type 2 diabetes study found the majority of its Afrezza-inhaling test subjects experiencing low blood sugar. The type 1 diabetes results achieved target levels that weren’t as effective as injection-based insulin that’s already on the market.

In the end, these may be just minor setbacks given the clear appeal of needle-free insulin. It wouldn’t be a surprise to see MannKind Corporation (NASDAQ:MNKD) bounce back after the largely positive report.

Orbitz Worldwide, Inc. (NYSE:OWW) shares went on a steep descent after a large investor moved to sell a sizable chunk of its stake in the online travel portal. PAR Capital Management unloaded 8.1 million of its 24.6 million shares, and that’s a tenth of the total Orbitz Worldwide, Inc. (NYSE:OWW) outstanding shares.

PAR Capital Management made the move to diversify. It’s still holding on to most of its position. However, the market doesn’t appreciate the dramatic expansion of more shares floating around.

Portugal Telecom, SGPS (ADR) (NYSE:PT) disconnected with the market after dramatically slashing its once beefy 11% yield. The telco is struggling on its home turf, but things are faring even worse in Brazil, where eroding currencies and cost-control concerns are weighing on the bottom line.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.